| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4   |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids |
$ Total Asks |
# Bids |
# Asks |
Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
 | Owkin | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $279.77M | Series B-1 | 6/8/2022 | $50M | $1.46B | $45.70 | Bristol Myers Squibb | ||||
 | Parabilis Medicines | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $811.88M | Series F | 1/8/2026 | $305.25M | $681.2M | $6.16 | RA Capital Management, Fidelity, Janus Henderson Investors, Frazier Life Sciences, Soleus Capital, venBio Partners, Cormorant Asset Management, Nextech Invest, ARCH Venture Partners, Milky Way Investments, GV, T. Rowe Price, Marshall Wace, General Catalyst, Invus, Farallon Capital Management, Foresite Capital, Rock Springs Capital, HBM Healthcare Investments, Samsara BioCapital, Catalio Capital Management, Sixty Degree Capital, Alderline Group | ||||
 | Parsley Health | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $28.11M | Series 1 | 2/28/2025 | $15M | $20.94M | $0.05 | Undisclosed Investors | ||||
 | Qualified Health | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $165.06M | Series A-2 | 7/15/2026 | $10M | $769.76M | $37.62 | Undisclosed Investors | ||||
 | R-Zero | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $173.45M | Series C | 2/16/2023 | $105M | $526.86M | $14.13 | BMO Financial Group, Qualcomm Ventures, Upfront Ventures, DBL Partners, World Innovation Lab, Mayo Clinic, Bedrock Capital, SOSV, John Doerr | ||||
 | Rightway | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $338.4M | Series E | 8/25/2026 | $155M | $1.66B | $52.33 | Undisclosed Investors | ||||
 | SetPoint Medical | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $303.01M | Series D | 8/11/2025 | $115M | $471.62M | $1.51 | Elevage Medical Technologies, Ally Bridge Group, Northwell Health, SPRIG Equity, Norwest Venture Partners, New Enterprise Associates, Viking Global Investors, Action Potential Venture Capital, Abbott, Boston Scientific, Euclidean Capital, Richard King Mellon Foundation, Morgenthaler Ventures, ShangBay Capital, Ascendum Capital, Catalio Capital Management, Gilmartin Capital, Midas Capital | ||||
 | Soda Health | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Synthego | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $415.07M | Series E | 2/17/2022 | $144.17M | $1.3B | $10.78 | Perceptive Advisors, SoftBank, Declaration Partners, Laurion Capital Management, Logos Capital, GigaFund, Chimera Abu Dhabi, Wellington Management, RA Capital Management, Moore Strategic Ventures | ||||
 | TraceLink | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $278.43M | Series D | 8/21/2018 | $60M | $657M | $16.01 | Georgian Partners, Vulcan Capital, Willett Advisors, FirstMark Capital, Volition Capital, F-Prime Capital, Goldman Sachs | ||||
 | Upstream Bio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $800M | Series B | 6/8/2023 | $200M | $676.16M | $17.00 | Enavate Sciences, Venrock Healthcare Capital Partners, Bain Capital Life Sciences, Wellington Management, OrbiMed, Access Biotechnology, Decheng Capital, Altshuler Shaham Provident Funds Ltd., TCG X, HBM Healthcare Investments, Omega Funds, Samsara BioCapital | ||||
 | Vanqua Bio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $149.15M | Series B | 7/12/2024 | $130M | $333.4M | $4.06 | Omega Funds, OrbiMed, Citadel, Avoro Ventures, Casdin Capital, Pontifax, Eli Lilly and Company, Logos Capital, Osage University Partners | ||||
 | ZAP Surgical Systems | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Affinia Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $219.17M | Series C | 10/7/2025 | $40M | $156.61M | $1.62 | New Enterprise Associates, Eli Lilly, Alexandria Venture Investments, Atlas Venture, Avidity Partners, F-Prime Capital, GV, Mass General Brigham Ventures, Perceptive Advisors | ||||
 | Ajax Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | BillionToOne | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $396.39M | Series D | 6/21/2024 | $130.47M | $1.25B | $28.02 | Premji Invest, Neuberger Berman, Adams Street Partners, Baillie Gifford, Hummingbird Ventures, Civilization Ventures, Libertus Capital, Fifty Years | ||||
 | C4 Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Cadence Solutions | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $243.46M | Series C | 6/23/2026 | $100M | $1.2B | $4.60 | Spark Capital, Thrive Capital, General Catalyst, Coatue, B Capital, Corewell Health Ventures, Memorial Hermann, Duke Health | ||||
 | Centivo | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $332.61M | Series C | 7/14/2026 | $107.59M | $334.91M | $1.33 | Undisclosed Investors | ||||
 | Cerebral | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $25M | Series D | 9/12/2025 | $25M | $407.5M | $2.50 | Undisclosed Investors | ||||
 | Clear Labs | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $157.08M | Series D | 1/13/2025 | $30M | $395.17M | $2.80 | Counterpoint Global, Felicis, GV, HBM Genomics, Khosla Ventures, Menlo Ventures, Nimble Ventures, Redmile Group, Wing Venture Capital, T. Rowe Price Associates | ||||
 | Clipboard Health | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $187.23M | Series C | 4/18/2022 | $30M | $1.3B | $22.82 | Sequoia Capital | ||||
 | Diagonal Therapeutics | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $253M | Series B | 1/8/2026 | $125M | $447.42M | $2.70 | Sanofi Ventures, Janus Henderson Investors, Deep Track Capital, EcoR1 Capital, Logos Capital, Balyasny Asset Management, Woodline Partners, BVF Partners, Atlas Venture, Lightspeed Venture Partners, RA Capital Management, Frazier Life Sciences, Viking Global Investors, Velosity Capital, Checkpoint Capital, RV Invest, Biovision Ventures | ||||
 | Flare Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $290.35M | Series C | 6/30/2026 | $85M | $188.49M | $0.37 | Third Rock Ventures, Nextech Invest, Pfizer, Boxer Capital, GordonMD Global Investments, Invus, Casdin Capital, Eli Lilly and Company, Novartis, Agent Capital, Eventide Asset Management | ||||